Navigation Links
Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer
Date:10/20/2008

ACTON, Mass., Oct. 20 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced that Raymond J. Ruddy has joined the company as Vice President, Controller.

Ray will be responsible for all internal and external financial reporting activities, as well as the financial analysis and planning activities necessary for the company's continued growth. Ray will report directly to the Chairman and CEO.

Since 2005, Ray has served as Director of International Finance of GSI Group Corporation. From 2001 to 2005 Ray served as Director of Finance and Investor Relations of Concord Communications. He began his career in the audit department at Ernest & Young LLP and proceeded to work in positions of increasing responsibilities with three additional firms before joining Concord Communications. Ray is a CPA who received his BA from The College of the Holy Cross and his MBA from the Yale University School of Management.

Raymond C. Kubacki, Chairman and CEO stated, "We are extremely pleased to have Ray join our team. He comes to us with a strong proven track record that fits extremely well with the needs of our company. His strong analytical skills and broad experience base will be very important in determining and controlling costs and expenses, as well as analyzing other key metrics in our business needed to accelerate our growth. Ray will be our top financial officer and we are extremely pleased to have him on board."

Psychemedics is the world's largest provider of testing for drugs of abuse using hair analysis with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and Federal Reserve Banks.

The Psychemedics web site is http://www.drugtestwithhair.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning growth, earnings, profit margins, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward-looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact: Raymond C. Kubacki

Chairman, President and CEO

(978) 206-8220


'/>"/>
SOURCE Psychemedics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement by American Heart Association Immediate-Past President Raymond Gibbons, M.D. on Congressional Omnibus Spending Bill
2. SXC Health Solutions to present at Raymond James 29th Annual Institutional Investors Conference
3. Gentiva(R) Health Services to Present March 3rd at Raymond James 29th Annual Institutional Investors Conference in Orlando
4. MedCath Corporation to Present at the Raymond James 29th Annual Institutional Investors Conference
5. Hologic to Present at the Raymond James & Associates 29th Annual Institutional Investors Conference
6. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
7. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
8. Emageon to Present at Raymond James 29th Annual Institutional Investors Conference
9. Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors
10. Richard Greco Joins Mediware Board
11. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: